Loading...
Please wait, while we are loading the content...
Similar Documents
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia
| Content Provider | Scilit |
|---|---|
| Author | Tomowiak, Cécile Poulain, Stéphanie Herbaux, Charles Perrot, Aurore Mahé, Béatrice Morel, Pierre Aurran, Thérèse Tournilhac, Olivier Leprêtre, Stéphane Assaad, Souad Villemagne, Bruno Casasnovas, Olivier Nollet, Delphine Roos-Weil, Damien Chevret, Sylvie Leblond, Véronique |
| Copyright Year | 2021 |
| Description | We present the results of a phase 2 study evaluating the combination of obinutuzumab + idelalisib in relapsed/refractory (R/R) Waldenström macroglobulinemia (WM). The goal was to determine the safety and efficacy of a fixed-duration chemotherapy-free treatment. During the induction phase, patients received idelalisib + obinutuzumab for 6 cycles, followed by a maintenance phase with idelalisib alone for ≤2 years. Forty-eight patients with R/R WM were treated with the induction combination, and 27 patients participated in the maintenance phase. The best responses, reached after a median of 6.5 months (interquartile range, 3.4-7.1; range, 2.6-22.1 months), were very good partial response in 5 patients, partial response in 27 patients, and minor response in 3 patients, leading to overall response rate and major response rate estimates of 71.4% (95% confidence interval [CI], 56.7-83.4) and 65.3% (95% CI, 50.4-78.3), respectively. With a median follow-up of 25.9 months, median progression-free survival was 25.4 months (95% CI, 15.7-29.0). Univariate analysis focusing on molecular screening found no significant impact of CXCR4 genotypes on responses and survivals but a deleterious impact of TP53 mutations on survival. Although there was no grade 5 toxicity, 26 patients were removed from the study because of side effects; the most frequent were neutropenia (9.4%), diarrhea (8.6%), and liver toxicity (9.3%). The combination of idelalisib + obinutuzumab is effective in R/R WM. Nonetheless, the apparent lack of impact of genotype on outcome could give new meaning to targeting of the phosphatidylinositol 3-kinase pathway in WM. This trial was registered at www.clinicaltrials.gov as #NCT02962401. |
| Related Links | https://ashpublications.org/bloodadvances/article-pdf/5/9/2438/1806931/advancesadv2020003895.pdf |
| Ending Page | 2446 |
| Page Count | 9 |
| Starting Page | 2438 |
| DOI | 10.1182/bloodadvances.2020003895 |
| Journal | Blood advances |
| Issue Number | 9 |
| Volume Number | 5 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2021-05-11 |
| Access Restriction | Open |
| Subject Keyword | Hematology Idelalisib Survival Efficacy R/r Induction Maintenance Macroglobulinemia Relapsed/refractory Waldenström Journal: Blood advances (Vol- 106, Issue- 9) |
| Content Type | Text |
| Resource Type | Article |
